Trial Profile

Double Blind Randomised Placebo Controlled Evaluation of Single and Multiple Oral Doses of ATX2417 in Man and Effect of Food

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 14 Jan 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ATX 2417 (Primary)
Indications Asthma; Hypersensitivity
Focus Adverse reactions; First in man
Sponsors Atopix Therapeutics

Most Recent Events

12 Jul 2016 Status changed from recruiting to completed.
26 May 2015 According to ClinicalTrials.gov, treatment arms increased from 14 to 18; patient number changed from 56 to 72.
26 May 2015 Planned number of patients changed from 56 to 72 as reported by ClinicalTrials.gov

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com